{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:52:29Z","timestamp":1709081549989},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:p>There are conflicting reports on whether or not laboratory abnormalities in pediatric acquired von Willebrand syndrome (AVWS) predict bleeding manifestations in patients with cardiopulmonary disorders (CPD). We retrospectively reviewed charts of patients with AVWS and CPD (n=16) seen at Texas Children\u2019s Hospital from 2003 to 2012. The most common CPD were valve stenoses, ventricular septal defects, and pulmonary hypertension. All patients had loss of high molecular weight multimers. Fifteen (94%) patients presented with bleeding symptoms, with menorrhagia and epistaxis being the most common. Von Willebrand ristocetin cofactor activity (VWF:RCo), as well as the use of anticoagulant or antiplatelet medication, did not predict bleeding manifestations (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.70 and 0.84, respectively). VWF:RCo\/VWF antigen (Ag) ratio of &lt;0.7 was significantly associated with presence of bleeding symptoms. All patients who had complete repair of their cardiac defect experienced normalization of VWF multimers and VWF:RCo\/Ag ratio, as well as bleeding symptom resolution. We conclude that increased bleeding risk is associated with low VWF:RCo\/Ag ratio in pediatric AVWS due to CPD. However, other laboratory abnormalities such as VWF:RCo level and qualitative multimer analysis, do not appear to predict bleeding. Future studies exploring quantification of multimer loss may be helpful in further assessing bleeding risk associations.<\/jats:p>","DOI":"10.1097\/mph.0000000000000738","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T03:44:34Z","timestamp":1483674274000},"page":"121-125","source":"Crossref","is-referenced-by-count":8,"title":["Pediatric Acquired von Willebrand Syndrome in Cardiopulmonary Disorders: Do Laboratory Abnormalities Predict Bleeding Risk?"],"prefix":"10.1097","volume":"39","author":[{"given":"Saman K.","family":"Hashmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireya P.","family":"Velasquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald L.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiu-Ki","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi V.","family":"Srivaths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/s-0037-1613993","article-title":"Acquired von Willebrand syndrome: from pathophysiology to management","volume":"84","author":"Veyradier","year":"2000","journal-title":"Thromb Haemost"},{"key":"R3-20230918","first-page":"1","article-title":"Acquired von Willebrand syndrome in childhood and adolescence","volume":"1","author":"Will","year":"2009","journal-title":"J Coagul Disord"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0033-1334867","article-title":"Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update","volume":"39","author":"Federici","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1111\/hae.12567","article-title":"Acquired von Willebrand syndrome in paediatric patients with congenital heart disease: challenges in the diagnosis and management of this rare condition","volume":"21","author":"Avila","year":"2015","journal-title":"Haemophilia"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/bja\/aeq413","article-title":"Acquired type 2 A von Willebrand syndrome caused by aortic valve disease corrects during valve surgery","volume":"106","author":"Solomon","year":"2011","journal-title":"Br J Anaesth"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1055\/s-0037-1614188","article-title":"Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease: single center comparison of four different assays","volume":"84","author":"Federici","year":"2000","journal-title":"Thromb Haemost"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2516.2004.00894.x","article-title":"The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors\u2019 Organization","volume":"10","author":"Laffan","year":"2004","journal-title":"Haemophilia"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ajh.10298","article-title":"Acquired von Willebrand\u2019s syndrome: a single institution experience","volume":"72","author":"Kumar","year":"2003","journal-title":"Am J Hematol"},{"key":"R11-20230918","first-page":"424","article-title":"Autoantibody to von Willebrand factor in systemic lupus erythematosus","volume":"121","author":"Soff","year":"1993","journal-title":"J Lab Clin Med"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/blood.V92.8.2707","article-title":"Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches","volume":"92","author":"Federici","year":"1998","journal-title":"Blood"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1200\/JCO.1992.10.3.422","article-title":"Acquired von Willebrand disease in Wilms\u2019 tumor patients","volume":"10","author":"Coppes","year":"1992","journal-title":"J Clin Oncol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2516.2007.01642.x","article-title":"Hypothyroidism and acquired von Willebrand\u2019s syndrome: a systematic review","volume":"14","author":"Manfredi","year":"2008","journal-title":"Haemophilia"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/j.jpag.2011.04.004","article-title":"Idiopathic pulmonary hypertension causing acquired von Willebrand disease and menorrhagia","volume":"24","author":"Sokkary","year":"2011","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/icvts\/ivu305","article-title":"Shear-stress induced acquired von Willebrand syndrome in children with congenital heart disease","volume":"19","author":"Loeffelbein","year":"2014","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1182\/blood-2010-11-297580","article-title":"How I treat the acquired von Willebrand syndrome","volume":"117","author":"Tiede","year":"2011","journal-title":"Blood"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2012-10-435719","article-title":"Treatment of acquired von Willebrand syndrome in childhood","volume":"122","author":"Callaghan","year":"2013","journal-title":"Blood"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood.V67.3.758.758","article-title":"Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects","volume":"67","author":"Gill","year":"1986","journal-title":"Blood"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2143\/AC.62.4.2022285","article-title":"Frequency of acquired von Willebrand\u2019s disease in children with congenital heart disease","volume":"62","author":"Arslan","year":"2007","journal-title":"Acta Cardiol"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2141.2011.08732.x","article-title":"Acquired von Willebrand Syndrome in congenital heart disease: does it promote an increased bleeding risk?","volume":"155","author":"Onimoe","year":"2011","journal-title":"Br J Haematol"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/MAT.0000000000000084","article-title":"von Willebrand factor multimers in pediatric extracorporeal membrane oxygenation support","volume":"60","author":"Pasala","year":"2014","journal-title":"ASAIO J"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.healun.2015.12.024","article-title":"Longitudinal changes in hemostatic parameters and reduced pulsatility contribute to non-surgical bleeding in patients with centrifugal continuous-flow left ventricular assist devices","volume":"35","author":"Muthiah","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/CIRCHEARTFAILURE.109.877597","article-title":"Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device","volume":"3","author":"Meyer","year":"2010","journal-title":"Circ Heart Fail"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1213\/ANE.0000000000000554","article-title":"Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers","volume":"120","author":"Tauber","year":"2015","journal-title":"Anesth Analg"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/13543784.9.2.347","article-title":"Therapeutic approaches to acquired von Willebrand syndrome","volume":"9","author":"Federici","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1161\/01.CIR.102.20.2460","article-title":"Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension","volume":"102","author":"Veyradier","year":"2000","journal-title":"Circulation"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/heart.88.1.87","article-title":"Acquired von Willebrand syndrome in children with patent ductus arteriosus","volume":"88","author":"Rauch","year":"2002","journal-title":"Heart"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201703000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T05:52:29Z","timestamp":1695016349000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201703000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000738","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}